Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System
17 Octobre 2023 - 3:28PM
Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative
LIBERTY® Robotic Surgical System, today announces the successful
initial outcomes of using the LIBERTY Robotic Surgical System in
its pivotal pre-clinical study.
The pivotal study was conducted by three leading
interventional radiologists that utilized the LIBERTY Robotic
Surgical System to reach a total of 48 animal targets. A total of 6
LIBERTY Systems were used in the study, each was used to reach a
total of 8 targets. All 6 LIBERTY Systems performed flawlessly,
with 100% usability and technical success. No acute adverse events
or complications were visually observed intra-operative.
The company expects to receive the comprehensive
final report later this quarter. Subject to the final report, and
the completion of the verification and validation (V&V)
process, the Company plans on submitting the Investigational Device
Exemption (IDE) application to the FDA, in order to commence its
pivotal clinical trial in humans.
"We are extremely pleased with the LIBERTY
system performance during the pivotal pre-clinical study, both from
the usability and technical outcomes as well as the lack of visual
acute intraoperative complications. The system operated without any
issues in all cases, achieving our initial objectives for the
study," said Simon Sharon, CTO & GM. "We are continuing to take
all necessary steps towards submitting our IDE application to the
FDA and commencing our pivotal clinical trial."
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The LIBERTY® Robotic Surgical System aims to
improve the way surgical robotics are being used in endovascular
procedures today, by eliminating the need for large, cumbersome,
and expensive capital equipment, while reducing radiation exposure
and physician strain. The Company believes the LIBERTY® Robotic
Surgical System’s remote operation has the potential to be the
first system to democratize endovascular interventional
procedures.
Further information about Microbot Medical is
available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of
potential products, including LIBERTY, the outcome of its studies
to evaluate LIBERTY, whether the Company’s core business focus
program and cost reduction plan are sufficient to enable the
Company to continue to focus on its LIBERTY technology while it
stabilizes its financial condition and seeks additional working
capital, any failure or inability to recruit physicians and
clinicians to serve as primary investigators to conduct regulatory
studies which could adversely affect or delay such studies,
uncertainty in the results of pre-clinical and clinical trials or
regulatory pathways and regulatory approvals, disruptions resulting
from new and ongoing hostilities between Israel and the
Palestinians, such as employees of Microbot and its vendors and
business partners being called to active military duty, any
lingering uncertainty resulting from the COVID-19 pandemic, need
and ability to obtain future capital, and maintenance of
intellectual property rights. Additional information on risks
facing Microbot Medical can be found under the heading “Risk
Factors” in Microbot Medical’s periodic reports filed with the
Securities and Exchange Commission (SEC), which are available on
the SEC’s web site at www.sec.gov. Microbot Medical disclaims any
intent or obligation to update these forward-looking statements,
except as required by law.
Investor Contact:
Michal
Efraty+972-(0)52-3044404IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Microbot Medical (NASDAQ:MBOT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024